icon
An official government website affiliated with the Government of the Kingdom of Saudi Arabia.
icon Thu 25 Jun 2026
Beta version
icon
Official Saudi government website domains end with gov.sa

All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.

icon
Government websites use the protocol. HTTPS for encryption and security.

All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.

icon
Registered with the Digital Government Authority under number:
20250831619
Suggestions

Drug Clinical Trials List

Display 751 - 760 from 768
Study Title Study Sponsor Status Study Drug Trial Phase Study Protocol Number Site
Phase 2, Single-Site, Open-Label, Randomized, 2-ArmParallel Study to Assess the Efficacy and Safety ofRyanodex® (EGL-4104) as Adjuvant Treatment inSubjects With Exertional Heat Stroke (EHS Eagle Pharmaceuticals Completed Dantrolene 2 EGL-4104-C-1502 King Fahad Medical City (Riyadh)
An Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SBC-102 (Sebelipase Alfa) in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency Synageva Completed Sebelipase alfa (SBC-102) 2 LAL-CL03 King Faisal Specialist Hospital and Research Center (Riyadh)
A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Sitagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes Intarcia Therapeutics Completed ITCA 650 3 ITCA 650-CLP-105 King Abdulaziz Medical City NG (Jeddah)_ King Abdulaziz Hospital NG (Al Ahsa)_ Imam Abdulrahman Al Faisal Hospital NG (Dammam)_ King Fahad Medical City (Riyadh)
A 3 Month, Multicenter, Double-Masked Safety and Efficacy Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients Alcon Completed Travoprost 0.004% / Timolol 3 C-12-008 King Khaled Eye Specialist Hospital (Riyadh)
"Phase 3, Open/Label Study to evaluate the safety and efficacy of TMC 435 plus Pegylated Interferon alfa-2a and Ripavirin administrated for 12 weeks in treatment-naïve Subjects with Chronic genotype 1 or genotype 4 HCV infection" Janssen-Cilag International NV Completed TMC435 (simeprevir) / Pegylated interferon alfa-2a (PegIFNα-2a) / Ribavirin (RBV) 3b TMC435HPC3014 King Faisal Specialist Hospital and Research Center (Riyadh)_ King Abdulaziz Medical City NG (Riyadh)_ King Khalid University Hospital (Riyadh)
Superiority of Insulin Glargine Lantus vs. NPH: Treat to Normoglycemia Concept.Effect of Insulin Glargine in Comparison to Insulin NPH in Insulin-nave People With Type 2 Diabetes Mellitus Treated With at Least One OAD and Not Adequately Controlled Sanofi Completed Lantus® / Glimepiride / human insulin [NPH] 3 LANTU_C_02762 King Fahad University Hospital (Al-Khobar), King Abdulaziz University Hospital (Jeddah)
An Open-Label, Multicenter, Multinational Study of the Safety, Efficacy and Pharmacokinetics of Asfotase Alfa (human recombinant tissue non-specific alkaline phosphatase fusion protein) in Infants and Children ≤ 5 Years of Age with Hypophosphatasia (HPP). Alexion Completed Asfotase Alfa 2 ENB-010-10 King Faisal Specialist Hospital and Research Center (Riyadh)
Efficacy and Safety of Long-Term (6 Months) Innohep® Treatment Versus Anticoagulation With a Vitamin K Antagonist (Warfarin) for the Treatment of Acute Venous Thromboembolism in Cancer Patients Leo Completed Innohep (Tinzaparin) / Warfarin 3 IN 0901 INT King Abdulaziz Medical City NG (Riyadh), King Fahad Specialist Hospital (Dammam), King Abdulaziz University Hospital (Jeddah), King Khalid University Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh)
Efficacy and Safety of Irbesartan/Amlodipine Fixed Combination Therapy Compared With Irbesartan Monotherapy in Hypertensive Patients Uncontrolled on Irbesartan 150 mg Monotherapy Sanofi Completed Irbesartan Amlodipine 3 IRBAM_R_04219 King Abdulaziz Medical City NG (Jeddah)
Tocilizumab Efficacy and Safety in RA Patients After Inadequate Response to DMARDs or Anti-TNF Roche Completed Tocilizumab 3 ML22726 King Fahad Specialist Hospital (Dammam), King Fahad Medical City (Riyadh), King Abdulaziz University Hospital (Jeddah), Hira Hospital (Makkah)